Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats
VS-5584 is a small-molecular compound that showed equivalent activity against mTOR and all class I PI3K isoforms and demonstrated preclinical activity in diverse cancer cell lines and xenograft tumor model, and rational combination of VS-5584 and other target therapies achieved promising outcomes in...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Analytical Methods in Chemistry |
| Online Access: | http://dx.doi.org/10.1155/2020/8811522 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547698425724928 |
|---|---|
| author | Chunling Zhou Xiaoxin Li Aiping He Tianzhu Liu Jinmiao Tian Meihua Jiang Lina Fang |
| author_facet | Chunling Zhou Xiaoxin Li Aiping He Tianzhu Liu Jinmiao Tian Meihua Jiang Lina Fang |
| author_sort | Chunling Zhou |
| collection | DOAJ |
| description | VS-5584 is a small-molecular compound that showed equivalent activity against mTOR and all class I PI3K isoforms and demonstrated preclinical activity in diverse cancer cell lines and xenograft tumor model, and rational combination of VS-5584 and other target therapies achieved promising outcomes in oncology. In the present study, we established and validated a simple and sensitive UPLC-MS/MS method for the determination of VS-5584 in plasma samples. VS-5584 was separated via an Acquity UPLC BEH C18 column, with a mobile phase composed of acetonitrile and 0.2% formic acid in water (40 : 60). The calibration curve displayed a good linearity in the range of 1.0–1000 ng/mL, with satisfactory accuracy (−13.6% < RE% < 8.8%) and precision (CV%, less than 9.2%). The validated method was then applied to a pharmacokinetic study in rats. After administration of 10 mg/kg, VS-5584 was absorbed quickly and reached a peak concentration of 473.2 ± 72.0 ng/mL after 20 min. The established method allows for the quantification of VS-5584 in rat plasma in detail and can be utilized to successfully describe the pharmacokinetic profile of VS-5584. |
| format | Article |
| id | doaj-art-4744dec1897841fc8fcb5180e179322d |
| institution | Kabale University |
| issn | 2090-8865 2090-8873 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Analytical Methods in Chemistry |
| spelling | doaj-art-4744dec1897841fc8fcb5180e179322d2025-02-03T06:43:42ZengWileyJournal of Analytical Methods in Chemistry2090-88652090-88732020-01-01202010.1155/2020/88115228811522Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in RatsChunling Zhou0Xiaoxin Li1Aiping He2Tianzhu Liu3Jinmiao Tian4Meihua Jiang5Lina Fang6Liaoning Institute for Drug Control, Liaoning Inspection, Examination & Certification Centre, Shenyang 110035, ChinaLiaoning Institute for Drug Control, Liaoning Inspection, Examination & Certification Centre, Shenyang 110035, ChinaLiaoning Institute for Drug Control, Liaoning Inspection, Examination & Certification Centre, Shenyang 110035, ChinaLiaoning Institute for Drug Control, Liaoning Inspection, Examination & Certification Centre, Shenyang 110035, ChinaLiaoning Institute for Drug Control, Liaoning Inspection, Examination & Certification Centre, Shenyang 110035, ChinaCollege of Pharmacy, Shenyang Medical College, Shenyang 110034, ChinaCollege of Pharmacy, Shenyang Medical College, Shenyang 110034, ChinaVS-5584 is a small-molecular compound that showed equivalent activity against mTOR and all class I PI3K isoforms and demonstrated preclinical activity in diverse cancer cell lines and xenograft tumor model, and rational combination of VS-5584 and other target therapies achieved promising outcomes in oncology. In the present study, we established and validated a simple and sensitive UPLC-MS/MS method for the determination of VS-5584 in plasma samples. VS-5584 was separated via an Acquity UPLC BEH C18 column, with a mobile phase composed of acetonitrile and 0.2% formic acid in water (40 : 60). The calibration curve displayed a good linearity in the range of 1.0–1000 ng/mL, with satisfactory accuracy (−13.6% < RE% < 8.8%) and precision (CV%, less than 9.2%). The validated method was then applied to a pharmacokinetic study in rats. After administration of 10 mg/kg, VS-5584 was absorbed quickly and reached a peak concentration of 473.2 ± 72.0 ng/mL after 20 min. The established method allows for the quantification of VS-5584 in rat plasma in detail and can be utilized to successfully describe the pharmacokinetic profile of VS-5584.http://dx.doi.org/10.1155/2020/8811522 |
| spellingShingle | Chunling Zhou Xiaoxin Li Aiping He Tianzhu Liu Jinmiao Tian Meihua Jiang Lina Fang Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats Journal of Analytical Methods in Chemistry |
| title | Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats |
| title_full | Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats |
| title_fullStr | Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats |
| title_full_unstemmed | Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats |
| title_short | Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats |
| title_sort | development of a uplc ms ms method for the quantification of vs 5584 and its application in pharmacokinetic studies in rats |
| url | http://dx.doi.org/10.1155/2020/8811522 |
| work_keys_str_mv | AT chunlingzhou developmentofauplcmsmsmethodforthequantificationofvs5584anditsapplicationinpharmacokineticstudiesinrats AT xiaoxinli developmentofauplcmsmsmethodforthequantificationofvs5584anditsapplicationinpharmacokineticstudiesinrats AT aipinghe developmentofauplcmsmsmethodforthequantificationofvs5584anditsapplicationinpharmacokineticstudiesinrats AT tianzhuliu developmentofauplcmsmsmethodforthequantificationofvs5584anditsapplicationinpharmacokineticstudiesinrats AT jinmiaotian developmentofauplcmsmsmethodforthequantificationofvs5584anditsapplicationinpharmacokineticstudiesinrats AT meihuajiang developmentofauplcmsmsmethodforthequantificationofvs5584anditsapplicationinpharmacokineticstudiesinrats AT linafang developmentofauplcmsmsmethodforthequantificationofvs5584anditsapplicationinpharmacokineticstudiesinrats |